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ABSTRACT
In the past it was difficult to identify children 
with hearing loss, and many newborns remained 
undiagnosed, but since early 2000, when 
Universal Newborn Hearing Screening (UNHS) 
came into place and made successful strides 
in hearing loss research and have been able to 
provide screening of hearing loss at an early 
age of one month, hence they have been able 
to receive comprehensive treatment. UNHS 
also tracks infants for further follow up and 
wherever necessary. The two main methods used 
in newborn screening are otoacoustic emission 
and automated auditory brain stem response. 
Medical evaluation should begin as soon as 
possible when hearing loss is suspected, so as to 
complete prenatal, medical, and family history. 
Demands have been made to use DNA testing 
in detecting the molecular basis of hereditary 
hearing loss. The identification of genes and gene 
defects faces a lot of challenges due to the fact, 
there is tremendous genetic heterogeneity, but 
despite that, there has been successful genetic 
studies of hearing loss in isolated populations 
and consanguineous families. Hearing loss 
is common in patients with mitochondrial 
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disorders, affecting over half of all cases at some 
time in the course of the disease. Hearing loss has 
seen some research undertaken to the point now 
that deafness can be treated and this is through 
cochlea implantation.
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INTRODUCTION
Hearing loss that is manifested as the single phenotype 
in deaf patients is classified as a non-syndromic deafness 
and accounts for 70% of the total cases, whereas in 30% of 
the cases, deafness occurs as one of multiple phenotypic 
syndromic manifestations [1]. Hearing loss has a genetic 
etiology in the majority of cases and is very common. The 
universal newborn hearing screening program, together 
with remarkable recent progress in the characterization 
of genes associated function of hearing, have resulted in 
increased demand and exciting possibilities of detecting 
the molecular basis of hereditary hearing loss through 
DNA testing [2, 3].
In the past, a screening approach with inclusion of 
only high risk infants failed to identify at least 50% of 
children with hearing loss, and many newborns without 
risk factors remained undiagnosed until after 18 months 
of age, if diagnosis and intervention take place before 6 
months of age, however, an almost age appropriate level 
of language skills can be accomplished [2]. In 2000, the 
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joint committee on Infant hearing has endorsed Universal 
Newborn Hearing Screening (UNHS). The aim is to 
provide hearing screening to all newborns before the age 
of 1 month, with confirmation of hearing loss in infants 
who do not pass the initial, or a subsequent screening, 
through an audio logic evaluation by the age of three 
months. Comprehensive treatment can then be initiated 
before the age of 8 months. Most children identified this 
program have parents with normal hearing [4].
Hearing loss can be identified by several different 
complementary methods. Following the guidelines from 
the National Institutes of Health, all United States have 
adopted UNHS, but testing algorithms and requirements 
vary.
The two main methods used in newborn screening 
are optoacoustic emission and automated auditory brain 
stem response [5]. Despite the fact that UNHS has its 
own limitations, it is the first step towards a successful 
and cost-effective program. The main goal for UNHS 
is the diagnosis and management, normal language 
development and long term success after intervention. 
There are developments for data management and 
tracking of infants for follow up.
As soon as hearing loss is suspected, medical 
evaluation should begin as soon as possible so to 
complete prenatal, medical, and family history. Some of 
the risk factors that should be checked during this time 
include low birth weight, difficulties in breathing and 
chromosome abnormalities [6]. Laboratory testing should 
be individualized and directed toward the suspected 
diagnosis [7]. Identification of the cause of hearing loss is 
the highest priority of parents who learn that their child 
is hearing impaired [8].
Molecular diagnostics
As mentioned earlier that the characterization of genes 
associated with function of hearing, have resulted in 
increased demand and exciting possibilities of detecting 
the molecular basis of hereditary hearing loss through 
DNA testing [8]. Tremendous progress has been made 
in our understanding of the molecular basis of hearing 
and hearing loss. New molecular mechanisms of hearing 
impairment have been unveiled through recent that 
have been made in trying to understand the fascinating 
biology of the auditory system. Diagnostic impact of 
genetic testing has seen some changes take place, as well 
as exciting developments in therapeutic options. 
It is estimated that in the near future, Molecular 
diagnosis, which is already a reality for several hearing-
associated genes, will doubtlessly continue to increase, 
both in terms of the number of mutations tested and the 
spectrum of genes [9]. 
Genetic analysis for hearing loss is mostly used 
for diagnosis and treatment, and relatively rare for 
reproductive decisions, in contrast to other inherited 
disorders. Impressive genetic heterogeneity is what 
characterizes Inherited hearing loss. An abundance of 
genes carries a large number of mutations [10–12], but 
specific mutations in a single gene may lead to syndromic 
or non-syndromic hearing loss.
Hearing loss is a major public health concern, 
because it is common to all ages and affects 6 to 8% of 
the population in developed nations when all causes are 
combined and it is the most common birth defect [13, 14]. 
Following the implementation of the UNHS the incidence 
was found to be even higher than previously thought. 
With the vast research that been going on for a while, it 
has been found that 1 in 1000 newborn are deaf, one in 
300 children are affected with congenital hearing loss of 
a lesser degree, and an additional one in 1000 become 
profoundly hearing impaired before adulthood [15]. 
Before the implementation of early hearing detection 
and intervention programs, the average age at diagnosis 
was 1.5 to 3 years, which is well beyond the beginning of 
the critical interval for speech and language acquisition 
[16]. Undiagnosed hearing loss and diagnostic delay 
have a profound impact on linguistic and communicative 
competence, as cognitive psychosocial development. 
Delayed recognition may lead to isolation later in life.
There are several factors that can lead to hearing loss 
in one way or the other, the factors may be, environmental 
factors, genetic defects, or a combination thereof [16]. 
The best scenario we are going to use is the U.S, whereby 
hearing loss, is commonly caused by environmental 
factors such as prematurity, infections, exposure to 
ototoxic medications, and trauma. It is estimated that 
at least 50% prelingual hear loss is caused by genetic 
changes [17], whereas the etiology remains obscure 
in the remaining 25%. Most of these cases, however, 
are assumed to be of genetic origin. Hence the largest 
proportion of hearing loss causes is accounted genetically 
[18].
Genetic testing for hearing loss
Hearing loss can follow a pattern of autosomal 
recessive, autosomal dominant, X-linked, and 
mitochondrial inheritance. The genetic basis is highly 
complex. Recessive and dominant hearing loss can be 
caused by Allelic mutations in some genes. Mutations in 
the same genes can cause syndromic and non-syndromic 
hearing loss [19], and recessive hearing loss may be 
caused by a combination of two mutations in different 
genes from the same functional group.
The identification of genes and gene defects faces a lot 
of challenges due to the fact; there is tremendous genetic 
heterogeneity [19, 20]. Considering the complexity of the 
auditory system, which requires interaction of a diversity 
of proteins including ion channels, extracellular matrix, 
cytoskeletal proteins, and transcription factors, this is 
not surprising. However, it hampers gene identification 
by traditional genetic methods such as he grouping of 
multiple families for linkage analysis [21].
Genetic studies of hearing loss have been successful 
in isolated populations and consanguineous families. 
Even after the gene has been localized to a region on a 
chromosome, however, the process of positional cloning 
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via a physical map followed by transcript identification 
can be arduous. Some identified loci, including DFNB1, 
DFNA2, and DFNA3, have been found to harbor 
multiple genes [22]. Recent advances in genomics has 
greatly facilitated the identification of genes. In the 
field of non-syndromic hearing loss, 21 genes associated 
with autosomal recessive inheritance, 20 associated 
with autosomal dominant inheritance, and one with 
X-linked recessive transmission have been identified and 
characterized [22, 23].
Genetic factors play a major role in up to two thirds 
of all childhood hearing impairment. Molecular genetic 
testing assists otologists by providing insight into the 
etiology of hearing impairment in children. 50 to 100 
genes are estimated to be involved in the functioning 
of the ear. Mutations in any of those genes may cause 
hearing loss [24].
Mitochondrial hearing loss
Hearing loss can be of two types, either it is 
sensorineural or conductive. But in this article will shall 
be majoring mostly on sensorineural hearing loss [17]. Dr. 
Peter Kullar, Clinical Research Fellow at the Wellcome 
Trust Research Centre for Mitochondrial Disease at 
Newcastle University (UK), defines sensorineural hearing 
loss as the changes within the cochlea or within the nerves 
that lead to the brain [18].
Mitochondrial diseases are disorders caused by 
impairment of the mitochondrial respiratory chain. The 
genetic error can affect both mitochondrial DNA (mtDNA) 
and nuclear DNA (nDNA) [2]. MtDNA mutations 
are classified as either large scale rearrangements 
(duplications) which are usually sporadic or point 
mutations, which are usually maternally inherited, and 
concern genes responsible for protein synthesis (rRNAs 
or tRNAs) [8, 9, 19, 25], or genes encoding subunits of 
the electron transport chain (ETC) [20]. The phenotypic 
reaction of mtDNA mutations depends on the affected 
gene, its tissue distribution, and the different dependency 
of different organs and tissues on the mitochondrial 
energy supply. Visual and auditory pathways, heart, 
central nervous system (CNS), and skeletal muscle are 
the tissues mostly involved, because of their dependence 
on aerobic energy production.
Hearing loss is common in patients with mitochondrial 
disorders, affecting over half of all cases at some time in the 
course of the disease. Although the final common pathway 
for the hearing loss is thought to involve ATP deficiency 
secondary to a biochemical defect of the respiratory chain, 
the clinical presentation of mitochondrial deafness varies 
considerably, both in terms of associated clinical features 
and of natural history [21]. In some patients’ deafness 
is only part of a multisystem disorder, often involving 
the central nervous system, neuromuscular system, or 
endocrine organs in other cases, deafness may represent 
a feature of an oligo syndromic disease.
By contrast, there are also a number of mitochondrial 
“pure” deafness disorders; maternally inherited deafness 
is the most common due to the A1555G mutation in the 12 
s rRNA gene, MTRNR1 [26]. The use of streptomycin and 
a lesser extent other aminoglycoside antibiotics can cause 
hearing loss genetically susceptible individuals. These 
drugs are known to exert their antibacterial effects at the 
level of the decoding site of the small ribosomal subunit, 
causing miscoding or premature termination of protein 
synthesis. The hearing loss is primarily high frequency 
and may be unilateral. Risk factors for aminoglycoside 
ototoxicity include therapy lasting more than seven days, 
elevated serum levels, prior exposure to aminoglycosides, 
noise exposure, and high daily dose [22].
Several mutations in the MTRNR1 gene encoding 
the 12S rRNA (961delT/insC, T1095C, C1494T, A1555G 
[27–30], and probably A827G, T1005C and A1116G) and 
possibly also mutations (G7444A) in the COI/MTTS1 
gene overlap can contribute to ototoxic hearing loss. 
The MTRNR1 probably alter the secondary structure of 
the 12S rRNA molecule, so that it resembles its bacterial 
counterpart, the 16S rRNA, more closely. Mitochondrial 
noon syndromic sensory neural hearing loss (SNHL) is 
also associated with the A7445G, 7472insC, T7510C, and 
T7511C mutations in the tRNASer (UCN) gene, MTTS1 
[24].
The pathological examinations of the inner hear is 
technically demanding, highly specialized, and only 
possible postmortem. There have, therefore, only been a 
few detailed pathological studies of the auditory system 
in patients with mitochondrial diseases [23]. In the 
cochlea, the stria vascularis maintains the ionic gradient 
necessary for sound transduction and the complex 
interaction between inner and outer hair cells. These 
relative deficiency of intracellular ATP would impair the 
function of both the stria and the air cells, ultimately 
leading to cell death, possibly through apoptosis.
Hearing loss is usually peripheral (due to cochlea 
or auditory nerve dysfunction), but in patients with a 
multisystem mitochondrial disorder, the auditory system 
may be affected at the brain stem, midbrain or at a higher 
level in the auditory cortex [24]. The peripheral hearing 
loss typically affects high frequencies first, followed 
by intermediate frequencies, and finally involving low 
frequencies and causing the typical “flat” audiogram 
seen in a severely deaf individual [16]. The preferential 
involvement of high frequencies [16, 25] may be related 
to the relatively high energy requirements of the basal 
cochlea. The vast majority of patients with mitochondrial 
deafness have absent optoacoustic emission, providing 
strong evidence that the cochlea is the component most 
sensitive to mitochondrial dysfunction [26].
The degree of hearing loss correlates well with the 
mutation load in skeletal muscle, and the progressive 
nature of the hearing loss may be related to the 
accumulation of mutated mtDNA within the cochlea [11, 
27]. Although this appears to be the general trend, there 
are clear exceptions to the rule. In one patient with the 
A323G mutation, severe hearing loss was associated with 
low levels of mutated mtDNA in skeletal muscle [28, 
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29]. This may occur because of unequal segregation of 
mutated mtDNA among different tissues during early 
development, so that occasionally, by chance high levels 
are present in the cochlea precursors, and lower levels in 
skeletal muscle precursor cells [28]. 
As mentioned earlier that we shall be studying only 
syndromic form of mitochondrial SNHL, showing that 
the frequency of hearing loss in our group of patients is 
the same of the most of studies reported in literature [29].
Treatment
Deafness is the only sensory defect that can be 
treated successfully even if the deafness is complete. 
A recent cochlear implant in children of 8 to 9 years of 
age who received their implants before the age of five, 
demonstrated that all children benefited from cochlear 
implantation in the areas of speech production, speech 
perception and language [2, 17, 30]. There was a 
significant positive difference in cognitive and reading 
performance in children with identified GJB2 mutations, 
which cause an isolated insult to the cochlea without 
damage to the Vilith nerve or the central auditory system.
Even though the hearing loss in other children may 
be non-syndromic and isolated in appearance, the 
underlying etiologies are likely to include asymptomatic 
congenital cytomegalovirus (CMV) and undiagnosed 
meningitis. Thus these children are likely to face SNHL 
with subtle additional disabilities due to central effects. 
Cochlea implant surgery has also been performed in 
patients with MELAS, maternally inherited diabetes and 
deafness. Even though a variety of mutations can cause 
mitochondrial hearing loss and although variable severity 
as well as progression after initial onset are characteristic, 
cochlea surgery has been highly beneficial. This strongly 
suggests that the pathological changes resulting from the 
mtDNA mutations primarily affect the cochlea [30].
CONCLUSION 
A lot of credit needs to be given to the field of 
hearing loss and deafness because of the strides they 
have taken in the areas of research, newborn screening, 
molecular diagnosis, and treatment. Hearing loss can 
now be identified early, and early confirmation results in 
possibility of more inclusive usage of language and speech. 
In the cases of non-syndromic SNHLGJB2 mutation 
analysis should always be offered, preferably instep 
wise combination with GJB6 testing. Mitochondrial 
inheritance and testing should be considered in any 
family with multiple affected individuals. When more 
assays become available, molecular testing could become 
the first in the casual determination while more invasive 
testing may be avoided. Once cause is established, 
treatment such as cochlea implantation can dramatically 
improve communication and quality of life for many 
patients.
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